Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keytruda Rules The Roost, But Merck & Co. Highlights Progress In Other Areas

Executive Summary

Merck & Co. outlined its near-term growth drivers during an investor day, including Keytruda in breast and prostate cancer, as well as vaccines for RSV and CMV, a drug for chronic cough and a long-acting HIV medicine.

You may also be interested in...



Merck Buys Peloton On Eve Of IPO, Expands Kidney Cancer Portfolio

Investors in Peloton, which has the only clinical-stage HIF-2α inhibitor, will get back 3.5 times the $304m in venture capital invested in the firm via the $1.1bn that Merck is paying up front. With all $1.15bn in additional milestone fees, the return could grow to 7.2x.

Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors

CEO Ken Frazier had to argue the case that Merck has a diversified portfolio in yet another strong quarter for the PD-1 inhibitor Keytruda.

First In 10 Years, But Lenvima's First-Line Liver Label Could Be Challenged Soon

Eisai and Merck won the first US FDA approval in 10 years for a first-line hepatocellular carcinoma treatment with Lenvima, but challengers are on the horizon. The companies' recent partnership and plans for combination therapy with Keytruda may defend the drug's standing in liver cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125428

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel